|
Characteristics
|
Live birth (n = 25)
|
Ongoing pregnancy (n = 43)
|
|---|
|
Study characteristics
|
|
Median (range) study sample size
|
355 (38–1983)
|
237 (38–1983)
|
|
Continent
|
|
North America
|
5 (20)
|
9 (21)
|
|
Europe
|
9 (36)
|
17 (40)
|
|
Asia
|
7 (28)
|
11 (26)
|
|
World wide
|
2 (8)
|
2 (5)
|
|
Other
|
2 (8)
|
4 (9)
|
|
Type of interventions/controls
|
|
Placebo/no LPS treatment
|
2 (8)
|
6 (14)
|
|
HCG
|
2 (8)
|
5 (12)
|
|
Progesterone
|
24 (96)
|
39 (91)
|
|
Combineda
|
6 (24)
|
11 (26)
|
|
Patient characteristics
|
|
Median (range) age (years); No in group
|
32.4 (28.4–35.5); n = 24
|
32.1 (28.4–35.4); n = 40
|
|
Ovarian stimulation
|
|
Long GnRH agonist protocol
|
14 (56)
|
24 (56)
|
|
GnRH antagonist protocol
|
1 (4)
|
5 (12)
|
|
Other protocol
|
4 (16)
|
6 (14)
|
|
Combined
|
6 (24)
|
8 (19)
|
|
Fertilization
|
|
IVF
|
13 (52)
|
23 (53)
|
|
ICSI
|
2 (8)
|
7 (16)
|
|
IVF/ICSI
|
10 (40)
|
13 (30)
|
|
Timing LPS after oocyte retrieval
|
|
Within 48 h
|
18 (72)
|
31 (72)
|
|
48–96 h
|
4 (16)
|
12 (28)
|
|
Not stated
|
5 (20)
|
5 (12)
|
- a Combined progesterone with HCG, oestrogen or GnRH agonists. Abbreviations LPS luteal phase support, HCG human chorionic gonadotrophin, GnRH gonadotropin releasing hormone, IVF in vitro fertilization, ICSI intracytoplasmic sperm injection
